Declarations of interest Thorax: first published as 10.1136/thoraxjnl-2016-209333.467 on 15 November 2016. Downloaded from

P55 BENEFITS OF TIOTROPIUM/OLODATEROL ON B Make has received honoraria for participation in NOVELTY SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE IN planning meeting, and has received grant funding, participated in PATIENTS WITH MODERATE TO SEVERE COPD WITH advisory boards and provided non-branded talk for AstraZeneca. CHRONIC BRONCHITIS AND/OR EMPHYSEMA He has received honoraria for participation in medical advisory boards for Aerocrine, Boehringer-Ingelheim, CSL Bering, GlaxoS- 10.1136/thoraxjnl-2016-209333.467 mithKline, Forest, Novartis, Spiration, Theravance, and Suno- vion. He has participated in research studies funded by Boehringer-Ingelheim, GlaxoSmithKline, Pfizer, Forest, Sunovian. GT Ferguson, during the conduct of the study, reports grants, RJ Martin has received consulting fees from AstraZeneca, personal fees and non-financial support from Boehringer Ingel- Teva, Genentech, Boeringer Ingelheim, and PMD. His institution heim and, outside the submitted work, grants, personal fees and has received grants from NHLBI (AsthmaNet) and MedImmune. non-financial support from Boehringer Ingelheim, personal fees He has also received travel/accommodation/meeting expenses from GlaxoSmithKline, grants and personal fees from Novartis, from the Respiratory Effectiveness Group. AstraZeneca, Pearl Therapeutics and Sunovion, and grants from I Pavord has received speaker’s honoraria for speaking at Forest. sponsored meetings from Astra Zeneca, Boehringer Ingelheim, R Abrahams reports grants and personal fees from Boehringer Aerocrine, Almirall, Novartis, and GSK and a payment for organ- Ingelheim during the conduct of the study and, outside of this ising an educational event from AZ. He has received honoraria work, grants and personal fees from GlaxoSmithKline and grants for attending advisory panels with Almirall, Genentech, Regen- from AstraZeneca and Pearl Therapeutics. eron, Astra Zeneca, Boehringer Ingelheim, GSK, MSD, Schering- L Bjermer reports no conflicts of interest. Plough, Novartis, Dey, Napp and Respivert. He has received L Grönke and F Voß are employees of Boehringer Ingelheim sponsorship to attend international scientific meetings from Pharma GmbH & Co. KG. Boehringer Ingelheim, GSK, Astra Zeneca and Napp. D Singh reports other financial activities from Boehringer D Price has board membership with Aerocrine, Almirall, Ingelheim during the conduct of the study and, outside of the Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mun- submitted work, grants and personal fees from Almirall, AstraZe- dipharma, Napp, Novartis, and Teva Pharmaceuticals; consul- neca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, tancy with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Teva, Theravance and Verona, and personal fees from Genentech Pfizer, and Teva Pharmaceuticals; grants and unrestricted funding and SkyePharma. for investigator-initiated studies (conducted through Research in Real-Life Ltd and Observational and Pragmatic Research Institute Pte Ltd) from UK National Health Service, British Lung Founda- P138 AN INNOVATIVE APPROACH TO STUDY DESIGN: USING tion, Aerocrine, AKL Ltd, Almirall, AstraZeneca, Boehringer ELECTRONIC MEDICAL RECORDS TO INFORM THE Ingelheim, Chiesi, Eli Lilly, GlaxoSmithKline, Meda, Merck, FEASIBILITY AND DESIGN OF THE NOVELTY STUDY (A Mundipharma, Napp, Novartis, Orion, Pfizer, Respiratory Effec- NOVEL OBSERVATIONAL LONGITUDINAL STUDY ON tiveness Group, Takeda, Teva Pharmaceuticals, and Zentiva; pay- PATIENTS WITH ASTHMA AND/OR COPD) ments for lectures/speaking from Almirall, AstraZeneca, http://thorax.bmj.com/ Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, 10.1136/thoraxjnl-2016-209333.468 Meda, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, Takeda, and Teva Pharmaceuticals; payment for manuscript prep- The NOVELTY study is supported by AstraZeneca. aration from Mundipharma and Teva Pharmaceuticals; patents M Gerhardsson de Verdier, C Keen, A Gardev, S Rennard, A (planned, pending or issued) from AKL Ltd; payment for the Sveréus, L Brannman, N Karlson, J Nuevo, F Nyberg and S development of educational materials from GlaxoSmithKline and Young are employees of AstraZeneca. Novartis; stock/stock options from AKL Ltd which produces phy- HK Reddel has participated in advisory boards for AstraZe- topharmaceuticals; owns 80% of Research in Real Life Ltd, 75% on September 30, 2021 by guest. Protected copyright. neca, GlaxoSmithKline and Novartis, a data safety monitoring of the social enterprise Optimum Patient Care Ltd and 75% of board for AstraZeneca, GlaxoSmithKline, Merck and Novartis, Observational and Pragmatic Research Institute Pte Ltd; received has provided independent educational presentations for AstraZe- payment for travel/accommodations/meeting expenses from neca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma Aerocrine, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva, and has received independent research funding from and Teva Pharmaceuticals; funding for patient enrolment or com- AstraZeneca and GlaxoSmithKline. pletion of research from Almirall, Chiesi, Teva Pharmaceuticals, R Beasley has received research funding from Astra Zeneca, and Zentiva; and peer reviewer for grant committees of the Med- Genentech, Cephalon, GlaxoSmithKline, Novartis and Sanofi, ical Research Council (2014), Efficacy and Mechanism Evalua- and has received payments for lectures and/or participation in tion programme (2012), HTA (2014). advisory boards from AstraZeneca, GlaxoSmithKline and AT Bansal is a paid consultant of AstraZeneca, GlaxoSmithK- Novartis. line, hVivo and Roche. EH Bel received research grants from Roche, AstraZeneca, J Vestbo has received honoraria from AstraZeneca, Boeh- GlaxoSmithKline, and honoraria for research consulting from ringer-Ingelheim, Chiesi, GlaxoSmithKline and Novartis for AstraZeneca, GlaxoSmithKline, Novartis, and Sanofi/Regeneron. advising and presenting. C Janson has no disclosures to declare.

Thorax 2016;71(Suppl 3):A1–A288 A271